Accelerating the development of vaccine microarray patches for epidemic response and equitable immunization coverage requires investment in microarray patch manufacturing facilities

References

• Richardson LC, Moss WJ. Measles and rubella microarray array patches to increase vaccination coverage and achieve measles and rubella elimination in Africa. Pan Afr Med J. 2020;35(Suppl 1):3.
   PubMedGoogle Scholar
• Feinmann J. Covid-19: global vaccine production is a mess and shortages are down to more than just hoarding. BMJ. 2021;375:n2375.
   PubMedGoogle Scholar
• Mirasol F. Increases in manufacturing capacity target vial and syringe shortages. BioPharm Int. 2021;34(3):40–43.
   Web of Science ®Google Scholar
• Dakin J. Supply chain challenges creating hurdles to COVID-19 vaccine production. Pharm Technol. 2021;45(4):60–64.
   Google Scholar
• Braimoh T, Dimarco M There is a global shortage of nurses. COVID-19 is making it worse [Internet]. Boston (MA): Clinton Health Access Initiative; 2021 [cited 2022 Mar 24]; [ about 10 screens]. Available from: https://www.clintonhealthaccess.org/there-is-a-global-shortage-of-nurses-COVID-19-is-making-it-worse/
   Google Scholar
• Fritz J, Griffin G, Hammack R, et al. Syringes must be prioritized globally to ensure equitable access to COVID-19 and other essential vaccines and to sustain safe injection practices. Hum Vaccin Immunother. 2022 Jun 1;18(7):2077580.
   PubMed Web of Science ®Google Scholar
• Forster AH, Witham K, Depelsenaire ACI, et al., Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: results from a randomized, controlled phase I clinical trial. PLoS Med. 2020;17(3):e1003024.
   PubMed Web of Science ®Google Scholar
• Rouphael NG, Paine M, Mosley R, et al. TIV-MNP 2015 study group. The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trial. Lancet. 2017;390(10095):649–658.
   PubMed Web of Science ®Google Scholar
• Crommelin DJA, Anchordoquy TJ, Volkin DB, et al., Addressing the cold reality of mRNA VACCINE STABILITY. J Pharm Sci. 2021;110(3):997–1001.
   PubMed Web of Science ®Google Scholar
• Muramatsu H, Lam K, Bahus C, et al. Lyophilization provides long-term stability for a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine. Mol Ther. 2022;30(5):1941–1951.
   PubMed Web of Science ®Google Scholar
• Crommelin DJA, Volkin DB, Hoogendoorn KH, et al. The science is there: key considerations for stabilizing viral vector-based covid-19 vaccines. J Pharm Sci. 2021;110(2):627–634.
   PubMed Web of Science ®Google Scholar
• Pearson FE, McNeilly CL, Crichton ML, Pearson FE, McNeilly CL, Crichton ML, et al. Dry-coated live viral vector vaccines delivered by nanopatch microprojections retain long-term thermostability and induce transgene-specific T cell responses in mice. PLoS One. 2013;8(7):e67888.
   PubMed Web of Science ®Google Scholar
• Chen Y, Liao Q, Chen T, et al., Freeze-drying formulations increased the adenovirus and poxvirus vaccine storage times and antigen stabilities. Virol Sin. 2021;36(3):365–372.
   PubMed Web of Science ®Google Scholar
• O’Shea J, Prausnitz MR, Rouphael N. Dissolvable microneedle patches to enable increased access to vaccines against SARS-CoV-2 and future pandemic outbreaks. Vaccine. 2021;9(4):320.
   PubMed Web of Science ®Google Scholar
• Guillermet E, Alfa DA, Phuong Mai LT, et al. End-user acceptability study of the nanopatch™; a microarray patch (MAP) for child immunization in low and middle-income countries. Vaccine. 2019;37(32):4435–4443.
   PubMed Web of Science ®Google Scholar
• Becker L, Whorley M, Hess T, et al. Estimating the economic and public health impact of microarray patch (MAP)-administered vaccines in pandemics [Internet]. Washington (DC): Avalere Health; 2022 [cited 2022 Apr 4]; [ about 40 screens]. Available from: https://avalere.com/wp-content/uploads/2022/03/MAP-White-Paper.pdf
   Google Scholar
• Mvundura M, Frivold C, Janik Osborne A, et al. Vaccine innovation prioritisation strategy: findings from three country-stakeholder consultations on vaccine product innovations. Vaccine. 2021;39(49):7195–7207.
   PubMed Web of Science ®Google Scholar
• UNICEF. Immunization coverage estimates dashboard. 2022 [cited 2022 Oct 20];[ about 3 screens]. Available from: https://data.unicef.org/resources/immunization-coverage-estimates-data-visualization/.
   Google Scholar
• COVID-19 pandemic fuels largest continued backslide in vaccinations in three decades [press release]. UNICEF Latin America and the Caribbean [Internet]. 2022 July 18 [cited 2022 Oct 20];[about 6 screens]. Available from: https://www.unicef.org/lac/en/press-releases/covid-19-pandemic-fuels-largest-continued-backslide-vaccinations-in-three-decades
   Google Scholar
• Fernando GJP, Hickling J, Jayashi Flores CM, et al. Safety, tolerability, acceptability and immunogenicity of an influenza vaccine delivered to human skin by a novel high-density microprojection array patch (Nanopatch™). Vaccine. 2018;36(26):3779–3788.
   PubMed Web of Science ®Google Scholar
• Hirobe S, Azukizawa H, Hanafusa T, et al. Clinical study and stability assessment of a novel transcutaneous influenza vaccination using a dissolving microneedle patch. Biomaterials. 2015l;57:50–58.
   PubMed Web of Science ®Google Scholar
• Korkmaz E, Balmert SC, Sumpter TL, et al. Microarray patches enable the development of skin-targeted vaccines against COVID-19. Adv Drug Deliv Rev. 2021;171:164–186.
   PubMed Web of Science ®Google Scholar
• Kristensen D, Giersing B, Hickling J, et al. A global collaboration to advance vaccine product innovations - The Vaccine Innovation Prioritisation Strategy. Vaccine. 2021;39(49):7191–7194.
   PubMed Web of Science ®Google Scholar
• Gavi, the Vaccine Alliance. The Vaccine Innovation Prioritisation Strategy (VIPS) [Internet]. Geneva: Gavi, the Vaccine Alliance; 2021 [cited 2022 Jun 27]; [ about 6 screens]. Available from: https://www.gavi.org/our-alliance/market-shaping/vaccine-innovation-prioritisation-strategy
   Google Scholar
• Giersing B, Shah N, Kristensen D, et al. Strategies for vaccine-product innovation: creating an enabling environment for product development to uptake in low- and middle-income countries. Vaccine. 2021;39(49):7208–7219.
   PubMed Web of Science ®Google Scholar
• Gavi, the Vaccine Alliance. Vaccine microarray patches (MAPs): public summary of the VIPS Alliance Action Plan [Internet]. Geneva: Gavi, the Vaccine Alliance; 2021 [cited 2022 Jun 27]; [ about 12 screens]. Available from: https://www.gavi.org/sites/default/files/about/market-shaping/VIPS-Alliance-Action-Plan-for-MAPS_Public-Summary.pdf
   Google Scholar
• Creelman B, Frivold C, Jessup S, et al. Manufacturing readiness assessment for evaluation of the microneedle array patch industry: an exploration of barriers to full-scale manufacturing. Drug Deliv Transl Res. 2022;12(2):368–375.
   PubMed Web of Science ®Google Scholar
• Microneedle Array Patch Regulatory Working Group. [cited 2022 Oct 20];[ about 2 screens]. Available from: https://www.microneedleregulatory.org/
   Google Scholar
• Forster A, Junger M. Opportunities and challenges for commercializing microarray patches for vaccination from a MAP developer’s perspective. Hum Vaccin Immunother. 2022;18(4):2050123.
   PubMed Web of Science ®Google Scholar
• Gavi, the Vaccine Alliance. New collaboration makes further 100 million doses of COVID-19 vaccine available to low- and middle-income countries [Internet]. Geneva: Gavi, the Vaccine Alliance; 2020 [cited 2022 Jan 19]; [ about 5 screens]. Available from: https://www.gavi.org/news/media-room/new-collaboration-makes-further-100-million-doses-COVID-19-vaccine-available-low
   Google Scholar
• Towse A, Chalkidou K, Firth I, et al. How should the world pay for a coronavirus disease (COVID-19) vaccine? Value Health. 2021;24(5):625–631.
   PubMed Web of Science ®Google Scholar
• Moore LE, Vucen S, Moore AC. Trends in drug- and vaccine-based dissolvable microneedle materials and methods of fabrication. Eur J Pharm Biopharm. 2022;173:54–72.
   PubMed Web of Science ®Google Scholar
• Stein F. Risky business: COVAX and the financialization of global vaccine equity. Glob Health. 2021;17(1):112.
   PubMed Web of Science ®Google Scholar
• Kremer M, Levin JD, Snyder CM Designing advance market commitments for new vaccines [Internet]. Cambridge (MA): National Bureau of Economic Research (NBER); 2020. [cited 2022 Jun 27]; [ about 2 screens]. ( NBER Working Paper No. w28168). Available from: https://ssrn.com/abstract=3743901
   Google Scholar
• World Health Organization (WHO). WHO announces first technology recipients of mRNA vaccine hub with strong support from African and European partners [Internet]. Geneva: WHO; 2022 [cited 2022 Feb 23]; [ about 5 screens]. https://www.who.int/news/item/18-02-2022-who-announces-first-technology-recipients-of-mrna-vaccine-hub-with-strong-support-from-african-and-european-partners
   Google Scholar
• McKinsey & Company [Internet]. McKinsey & Company; c1996–2022. Africa needs vaccines. What would it take to make them here? 2021 Apr 14 [cited 2022 Jan 30]; [ about 30 screens]. Available from: https://www.mckinsey.com/industries/life-sciences/our-insights/africa-needs-vaccines-what-would-it-take-to-make-them-here
   Google Scholar
• Melissa K, Malvoti S, Cherian T, et al. Estimating the future global dose demand for Measles-Rubella microarray patches. Frontiers in Public Health. 2023. DOI: 10.1101/2022.08.11.22278665.
   Web of Science ®Google Scholar
• Vaxxas receives $8.2 million grant to support manufacturing scale-up in its Australian manufacturing facility. Business Wire [Internet]. 2022 Sep 20 [cited 2022 Oct 20]; [about 2 screens]. Available from: https://www.businesswire.com/news/home/20220915006111/en/Vaxxas-receives-8.2-million-grant-to-support-manufacturing-scale-up-in-its-Australian-manufacturing-facility
   Google Scholar